Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

Muhamed Baljevic, Robert Z. Orlowski

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy and has an increasing incidence and prevalence globally, and proteasome inhibitors (PIs) form the backbone of some of our most effective regimens for all phases of this disease in fit and frail patients. Areas covered: Strong understanding of the proteasome complex is increasingly important as the rapid development of new PIs and innovative myeloma therapies complicate the use of old and new combination regimens. We focus herein on the pharmacodynamics and pharmacokinetics of the approved PIs and others in development, including their safety and efficacy in corresponding clinical studies. Expert opinion: Advancements such as the first oral PI, ixazomib, with a more convenient route of administration and improved toxicity profile led to an improved quality of life, patient compliance, and all-oral combination regimens which are efficacious for long-term management of standard and high-risk MM. Novel pan-PIs, such as marizomib, hold the promise of superior clinical activity due to irreversible targeting of all multicatalytic proteinase complex subunits. Development of clinically validated biomarkers of PI sensitivity/resistance is required to inform utilization of the most optimal and effective, rationally targeted PI treatments for all MM patients.

Original languageEnglish (US)
Pages (from-to)459-473
Number of pages15
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume15
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Pharmacodynamics
Proteasome Inhibitors
Pharmacokinetics
Multiple Myeloma
Proteasome Endopeptidase Complex
Therapeutics
Investigational Therapies
Expert Testimony
Biomarkers
Hematologic Neoplasms
Patient Compliance
Toxicity
Quality of Life
Safety
Incidence

Keywords

  • Myeloma
  • pharmacodynamics
  • pharmacokinetics
  • proteasome inhibitors

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. / Baljevic, Muhamed; Orlowski, Robert Z.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 15, No. 6, 03.06.2019, p. 459-473.

Research output: Contribution to journalArticle

@article{bb573011f9144e17a4434b3eb2d71bee,
title = "Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma",
abstract = "Introduction: Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy and has an increasing incidence and prevalence globally, and proteasome inhibitors (PIs) form the backbone of some of our most effective regimens for all phases of this disease in fit and frail patients. Areas covered: Strong understanding of the proteasome complex is increasingly important as the rapid development of new PIs and innovative myeloma therapies complicate the use of old and new combination regimens. We focus herein on the pharmacodynamics and pharmacokinetics of the approved PIs and others in development, including their safety and efficacy in corresponding clinical studies. Expert opinion: Advancements such as the first oral PI, ixazomib, with a more convenient route of administration and improved toxicity profile led to an improved quality of life, patient compliance, and all-oral combination regimens which are efficacious for long-term management of standard and high-risk MM. Novel pan-PIs, such as marizomib, hold the promise of superior clinical activity due to irreversible targeting of all multicatalytic proteinase complex subunits. Development of clinically validated biomarkers of PI sensitivity/resistance is required to inform utilization of the most optimal and effective, rationally targeted PI treatments for all MM patients.",
keywords = "Myeloma, pharmacodynamics, pharmacokinetics, proteasome inhibitors",
author = "Muhamed Baljevic and Orlowski, {Robert Z.}",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/17425255.2019.1621839",
language = "English (US)",
volume = "15",
pages = "459--473",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

AU - Baljevic, Muhamed

AU - Orlowski, Robert Z.

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy and has an increasing incidence and prevalence globally, and proteasome inhibitors (PIs) form the backbone of some of our most effective regimens for all phases of this disease in fit and frail patients. Areas covered: Strong understanding of the proteasome complex is increasingly important as the rapid development of new PIs and innovative myeloma therapies complicate the use of old and new combination regimens. We focus herein on the pharmacodynamics and pharmacokinetics of the approved PIs and others in development, including their safety and efficacy in corresponding clinical studies. Expert opinion: Advancements such as the first oral PI, ixazomib, with a more convenient route of administration and improved toxicity profile led to an improved quality of life, patient compliance, and all-oral combination regimens which are efficacious for long-term management of standard and high-risk MM. Novel pan-PIs, such as marizomib, hold the promise of superior clinical activity due to irreversible targeting of all multicatalytic proteinase complex subunits. Development of clinically validated biomarkers of PI sensitivity/resistance is required to inform utilization of the most optimal and effective, rationally targeted PI treatments for all MM patients.

AB - Introduction: Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy and has an increasing incidence and prevalence globally, and proteasome inhibitors (PIs) form the backbone of some of our most effective regimens for all phases of this disease in fit and frail patients. Areas covered: Strong understanding of the proteasome complex is increasingly important as the rapid development of new PIs and innovative myeloma therapies complicate the use of old and new combination regimens. We focus herein on the pharmacodynamics and pharmacokinetics of the approved PIs and others in development, including their safety and efficacy in corresponding clinical studies. Expert opinion: Advancements such as the first oral PI, ixazomib, with a more convenient route of administration and improved toxicity profile led to an improved quality of life, patient compliance, and all-oral combination regimens which are efficacious for long-term management of standard and high-risk MM. Novel pan-PIs, such as marizomib, hold the promise of superior clinical activity due to irreversible targeting of all multicatalytic proteinase complex subunits. Development of clinically validated biomarkers of PI sensitivity/resistance is required to inform utilization of the most optimal and effective, rationally targeted PI treatments for all MM patients.

KW - Myeloma

KW - pharmacodynamics

KW - pharmacokinetics

KW - proteasome inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85067087043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067087043&partnerID=8YFLogxK

U2 - 10.1080/17425255.2019.1621839

DO - 10.1080/17425255.2019.1621839

M3 - Article

C2 - 31104525

AN - SCOPUS:85067087043

VL - 15

SP - 459

EP - 473

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -